-
2026 CASH Major Preview: Global Hematology Leaders Convene — Internati onal Forum Agenda Revealed
Organized by Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences, the 6th Annual Meeting of Chinese Alliance for Society of Hematology (CASH) will be held on Jan. 9-11, 2026, in Tianjin, China. Since its inaugural session in 2021, CASH has become one of the most influential academic events in the field of hematology. Looking back at the previous five sessions, the conference has invited top experts and scholars from both China and abroad, attracting millions of online and onsite participants. It has focused on national strategies,…
-
SABCS Expert Commentary | Professor Jin Feng: Precision Immunotherapy Adds New Evidence in Early Triple-Negative Breast Cancer—Gene Expression–Based Subtyping Predicts Response to Neoadjuvant Immunochemotherapy
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study entitled “Gene Expression–based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. This study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early-stage triple-negative breast…
-
SABCS Hot Commentary | Prof. Jiayi Chen: RadComp Study Releases Comparative Cardiac Outcomes of Proton vs Photon Therapy in Breast Cancer
Study Overview RadComp (NCT02603341) is a multicenter, prospective, randomized phase III trial designed to determine whether the reduction in cardiac radiation dose achieved with proton therapy, compared with photon therapy,…
-
SABCS China Voice | Prof. Mao Xiaoyun: A Nomogram Model Based on Mammographic Imaging to Accurately Predict NAC Efficacy
Study Overview Background Breast cancer remains one of the most common malignancies and a leading cause of cancer-related death among women worldwide, posing a serious threat to women’s health. Neoadjuvant…
-
Summit Dialogue | Professors Zhang Guojun & Michael Gnant: New Frontiers in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Editor’s note: For patients with HER2-positive breast cancer, neoadjuvant treatment strategies are rapidly evolving—from traditional dual HER2 blockade to the fast-emerging era of antibody–drug conjugates (ADCs). Recently, Chinese-developed anti-HER2 ADCs…
-
SABCS China Voice | Professor Wang Biyun: Beware of ER Loss — Study Reveals Poor Prognosis in Patients Converting from ER-Positive to ER-Negative
Study Overview Title Clinical Outcomes of ER-Positive to Negative Conversion Versus De Novo Triple-Negative Breast Cancer: Evidence from an ^18F-FES PET/CT–Guided Study Background During the course of disease, patients with…
-
SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Reshape Breast Cancer Neoadjuvant Therapy
Editor’s Note As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…
-
SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Redefine Neoadjuvant Breast Cancer Treatment
Study Overview Background With intensified adjuvant CDK4/6i therapy, the absolute improvement in invasive disease-free survival (IDFS) ranges from 4.9% to 7.6%. Given treatment-related adverse events and economic burden, identifying patients…
Connecting Medical Expertise through Media